Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder

Trial Profile

A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NSI 189 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Neuralstem
  • Most Recent Events

    • 02 Apr 2018 Status changed from active, no longer recruiting to completed, according to a Neuralstem media release.
    • 05 Dec 2017 Results published in the Neuralstem Media Release
    • 13 Nov 2017 According to a Neuralstem media release, the company will present additional clinical data at the American College of Neuropsychopharmacology (Dec 2017) and will have a Post-phase II meeting with the FDA in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top